3 models fit Bio-Techne Corp Common Stock and they disagree: 0 of 3 land within 15% of the average. The price is above every model.
Two or more of our models back this value.
Large premium(i)Silver66
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, Graham number, and Dividend discount.
ACCE opinionBio-Techne Corp Common Stock (TECH)
Fair value (3 models)
$32.47
ACCE price target
$67.03
Rating
Overvalued
Horizon
12 months
Fair value published on 21 Oct 2026, 13:04 CEST; previously $40.02 since 12 Oct 2026, 00:00 CEST.
ACCE price target published on 15 Oct 2026, 00:00 CEST; previously $62.00 since 21 Jun 2026, 00:00 CEST.
Rating published on 21 Oct 2026, 13:04 CEST.
Price used: $72.55 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, P/E comparison, and Graham number.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
123.4% above
-55.2% to fair value
ACCE score
62
out of 100
Analysts
8% buy
13 covering
P/E
62.6x
forward 34.6x
1-year return
+9.8%
Dividend yield
0.44%
Bio-Techne Corp Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Bio-Techne sells reagents, antibodies, and instruments used in life-science research and diagnostics, including the Simple Western and Lumit platforms and its Spatial Biology portfolio. Its franchise rests on a high-margin consumables base, with a 66.2% gross margin and a 27.9% operating margin, which gives it pricing power and recurring pull-through once a lab qualifies its assays. Top-line growth has stalled at 1.3%, so the investment case depends on margin durability and any re-acceleration in academic and biopharma research spending, which is the catalyst to watch. The stock trades at 62.5x trailing earnings but 34.6x forward, a gap that signals the market expects earnings to recover faster than sales. At an $11.4B market cap with a 9.0% ROE, returns on equity are modest for a company with these margins, which makes it worth a closer look at capital allocation and working capital before the thesis is accepted. The score of 62/100 and absence from major indices suggest it is a stock the broader market is not yet paying up for.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
high
Valuation stretched vs fundamentals
Trades 123.4% above the model fair value of $32.47 on a 62.6 trailing P/E and 32.8 EV/EBITDA, while revenue grew just 1.3% year over year.
moderate
Earnings growth flattered by base
Earnings rose 128.6% year over year against revenue growth of only 1.3%, so the jump likely reflects a weak prior period rather than durable expansion.
moderate
Price above ACCE target
Trades 8.2% above the ACCE price target of $67.03, and the 4.7% short interest suggests some investors are betting on a pullback.
AI research notes
AI-assisted·How I use AIWritten Oct 23, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Free cash flow over the last twelve months reached $263M, showing the business generates real cash despite slow sales growth.
Net margin of 15.0% and a debt to equity ratio of 0.14 suggest a profitable business that carries little borrowed money.
The company beat expected earnings per share by 6.5% in its latest quarter, with 0.49 reported against 0.46 expected.
Why it could disappoint
Revenue grew just 1.3% over the last year, well below the 5.5% yearly average of the past five years.
At $72.55, the shares trade 123.4% above the model fair value of $32.47, which is the consensus of three valuation models.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 4, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where TECH's valuation models land
Price
$72.55
Model fair value
$32.47
Model range
$18.72 to $49.92
Fair value $32.47
Price $72.55
The price is above the whole model range.
Model
Fair value
Upside
Discounted cash flow
Dividend discount
EV/EBITDA comparison
Graham number
P/E comparison
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores